The improvement of an anti-CD22 immunotoxin

References

• Reichert JM, Rosensweig CJ, Faden LB, Dewitz MC. Monoclonal antibody successes in the clinic. Nat Biotechnol 2005; 9:1073 - 1078
   Web of Science ®Google Scholar
• Zhang Q, Chen G, Liu X, Qian Q. Monoclonal antibodies as therapeutic agents in oncology and antibody gene therapy. Cell Res 2007; 17:89 - 99
   PubMed Web of Science ®Google Scholar
• Pastan I, Hassan R, Fitzgerald DJ, Kreitman RJ. Immunotoxin therapy of cancer. Nat Rev Cancer 2006; 6:559 - 565
   PubMed Web of Science ®Google Scholar
• Pastan I, Hassan R, FitzGerald DJ, Kreitman RJ. Immunotoxin treatment of cancer. Annu Rev Med 2007; 58:221 - 237
   PubMed Web of Science ®Google Scholar
• Kreitman RJ, Squires DR, Stetler-Stevenson M, Noel P, FitzGerald DJP, Wilson WH, et al. Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies. J Clin Oncol 2005; 23:6719 - 6729
   PubMed Web of Science ®Google Scholar
• Hassan R, Bullock S, Premkumar A, Kreitman RJ, Kindler H, Willingham MC, et al. Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res 2007; 13:5144 - 5149
   PubMed Web of Science ®Google Scholar
• Kreitman RJ, Wilson WH, White JD, Stetler-Stevenson M, Jaffe ES, Giardina S, et al. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol 2000; 18:1622 - 1636
   PubMed Web of Science ®Google Scholar
• Kreitman RJ, Margulies I, Stetler-Stevenson M, Wang QC, FitzGerald DJ, Pastan I. Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) toward fresh malignant cells from patients with B-cell leukemias. Clin Cancer Res 2000; 4:1476 - 1487
   Google Scholar
• Kreitman RJ, Fitzgerald DJ, Pastan I. Approach to the patient after relapse of hairy cell leukemia. Leuk Lymphoma 2009; 50:32 - 37
   PubMed Web of Science ®Google Scholar
• Salvatore G, Beers R, Margulies I, Kreitman RJ, Pastan I. Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display. Clin Cancer Res 2002; 8:995 - 1002
   PubMed Web of Science ®Google Scholar
• Lechleider R, Pastan I. Advances in the development of anti-CD22 immunotoxins containing Pseudomonas exotoxin for treatment of hematologic malignancies. J Cancer Sci Ther 2011; 3:050 - 052
   Google Scholar
• Weldon JE, Xiang L, Chertov O, Margulies I, Kreitman RJ, FitzGerald DJ, et al. A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity. Blood 2009; 113:3792 - 3800
   PubMed Web of Science ®Google Scholar
• Ho M, Kreitman RJ, Onda M, Pastan I. In vitro antibody evolution targeting germline hot spots to increase activity of an anti-CD22 immunotoxin. J Biol Chen 2005; 280:607 - 617
   PubMed Web of Science ®Google Scholar
• Bostrom J, Yu SF, Kan D, Appleton BA, Lee CV, Billeci K, et al. Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site. Science 2009; 323:1610 - 1614
   PubMed Web of Science ®Google Scholar
• Pastan I, Beers R, Bera TK. Recombinant immunotoxins in the treatment of cancer. Methods Mol Biol 2004; 248:503 - 518
   PubMedGoogle Scholar
• Rajagopal V, Pastan I, Kreitman RJ. A form of anti-Tac(Fv) which is both single-chain and disulfide stabilized: comparison with its single-chain and disulfide-stabilized homologs. Protein Eng 1997; 12:1453 - 1459
   Google Scholar
• Reidl LS, Friedman DF, Goldman J, Hardy RR, Jefferies LC, Silberstein LE. Structural basis of a conserved idiotope expressed by an autoreactive human B cell lymphoma. Evidence that a VH. CDR3 mutation alters idiotypy and specificity. J Immunol 1991; 147:3623 - 3631
   PubMed Web of Science ®Google Scholar
• Kimura H, Cook R, Meek K, Umeda M, Ball E, Capra JD, et al. Sequences of the VH and VL regions of murine monoclonal antibodies against 3-fucosyllactosamine. J Immunol 1988; 140:1212 - 1217
   PubMed Web of Science ®Google Scholar
• James LC, Roversi P, Tawfik DS. Antibody multispecificity mediated by conformational diversity. Science 2003; 299:1362 - 1367
   PubMed Web of Science ®Google Scholar
• Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney DW Jr, et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 2003; 421:756 - 760
   PubMed Web of Science ®Google Scholar
• Kelley RF, O'Connell MP. Thermodynamic analysis of an antibody functional epitope. Biochemistry 1993; 32:6828 - 6835
   PubMed Web of Science ®Google Scholar
• Kabat EA, Wu TT, Perry HM, Gottesman KS, Foeller C. Sequences of Proteins of Immunological Interest 1991; 5th Ed. Bethesda MD National Institutes of Health Publication 91-3242
   Google Scholar
• Lefranc MP. IMGT, the international ImMunoGeneTics database. Nucleic Acids Res 2001; 29:207 - 209
   PubMed Web of Science ®Google Scholar
• Yelton DE, Rosok MJ, Cruz G, Cosand WL, Bajorath J, Hellström KE, et al. Affinity maturation of the BR96 anti-carcinoma antibody by codon-based mutagenesis. J Immunol 1995; 155:1994 - 2004
   PubMed Web of Science ®Google Scholar
• Barbas CF, Burton DR. Selection and evolution of high affinity human anti-viral antibodies. Trends Biotechnol 1996; 14:230 - 234
   PubMed Web of Science ®Google Scholar
• Yang WP, Green K, Pinzsweeney S, Briones AT, Burton DR, Barbas DF. CDR walking mutagenesis for the affinity maturation of a potent human anti-HIV-1 antibody into the picomolar range. J Mol Biol 1995; 254:392 - 403
   PubMed Web of Science ®Google Scholar
• Low NM, Holliger P, Winter F. Mimicking somatic hypermutation: affinity maturation of antibodies displayed on bacteriophage using a bacterial mutator strain. J Mol Biol 1996; 260:359 - 368
   PubMed Web of Science ®Google Scholar
• Dekruif J, Boel E, Logtenberg T. Selection and application of human single-chain Fv antibody fragments from a semisynthetic phage antibody display library with designed CDR3 regions. J Mol Biol 1995; 248:97 - 105
   PubMed Web of Science ®Google Scholar
• Chowdhury PS, Pastan I. Improving antibody affinity by mimicking somatic hypermutation in vitro. Nat Biotechnol 1999; 17:568 - 572
   PubMed Web of Science ®Google Scholar
• Schier R, Bye J, Apell G, McCall A, Adams GP, Malmqvist M, et al. Isolation of high-affinity monomeric human anti-c-erbB-2 single chain Fv using affinity-driven selection. J Mol Biol 1996; 255:28 - 43
   PubMed Web of Science ®Google Scholar
• Chothia C, Lesk AM, Tramontano A, Levitt M, Smith-Gill SJ, Air G, et al. Conformations of immunoglobulin hypervariable regions. Nature 1989; 342:877 - 883
   PubMed Web of Science ®Google Scholar
• Al-Lazikani B, Lesk AM, Chothia C. Standard conformations for the canonical structures of immunoglobulins. J Mol Biol 1997; 273:927 - 948
   PubMed Web of Science ®Google Scholar
• Ueda H, Tsumoto K, Kubota K, Suzuki E, Nagamune T, Nishimura H, et al. Open sandwich ELISA: a novel immunoassay based on the interchain interaction of antibody variable region. Nat Biotechnol 1996; 14:1714 - 1718
   PubMed Web of Science ®Google Scholar
• Sasajima Y, Iwasaki R, Tsumoto K, Kumagai I, Ihara M, Ueda H. Expression of antibody variable region-human alkaline phosphatase fusion proteins in mammalian cells. J Immunol Methods 2010; 361:57 - 63
   PubMed Web of Science ®Google Scholar
• Hugo N, Weidenhaupt M, Beukes M, Xu B, Janson JC, Vernet T, et al. VL position 34 is a key determinant for the engineering of stable antibodies with fast dissociation rates. Protein Eng 2003; 16:381 - 386
   PubMedGoogle Scholar
• Tedder TF, Tuscano J, Sato S, Kehrl JH. CD22, a B lymphocyte-specific adhesion molecule that regulates antigen receptor signaling. Annu Rev Immunol 1997; 5:481 - 504
   Web of Science ®Google Scholar
• Mintz U, Sachs L. Changes in the surface membrane of lymphocytes from patients with chronic lymphocytic leukemia and Hodgkin's disease. Int J Cancer 1975; 15:253 - 259
   PubMed Web of Science ®Google Scholar
• Bannister D, Popovic B, Sridharan S, Giannotta F, Filée P, Yilmaz N, et al. Epitope mapping and key amino acid identification of anti-CD22 immunotoxin CAT-8015 using hybrid β-lactamase display. Protein Eng Des Sel 2011; 24:351 - 360
   PubMed Web of Science ®Google Scholar
• Du X, Nagata S, Ise T, Stetler-Stevenson M, Pastan I. FCRL1 on chronic lymphocytic leukemia, hairy cell leukemia and B-cell non-Hodgkin lymphoma as a target of immunotoxins. Blood 2008; 111:338 - 343
   PubMed Web of Science ®Google Scholar
• Berridge FV, Tan AS, Herst PM. Tetrazolium dyes as tools in cell biology: New insights into their cellular reduction. Biotechnol Annu Rev 2005; 11:127 - 152
   PubMedGoogle Scholar
• Benedict CA, MacKrell AJ, Anderson WF. Determination of the binding affinity of an anti-CD34 single-chain antibody using a novel, flow cytometry based assay. J Immunol Methods 1997; 2:223 - 231
   Web of Science ®Google Scholar
• Krauss J, Arndt MA, Martin AC, Liu H, Rybak SM. Specificity grafting of human antibody frameworks selected from a phage display library: generation of a highly stable humanized anti-CD22 single-chain Fv fragment. Protein Eng 2003; 16:753 - 759
   PubMedGoogle Scholar